Recombinant interleukin-18 protects against disseminated Candida albicans infection in mice

J Infect Dis. 2004 Apr 15;189(8):1524-7. doi: 10.1086/382955. Epub 2004 Apr 1.

Abstract

Endogenous interleukin (IL)-18 is necessary for host defense against candidiasis. Prophylactic treatment of Candida albicans-infected mice with recombinant murine (r) IL-18 decreased mortality, which was accompanied by a decreased outgrowth of yeasts in the kidneys 1 day after infection. Therapeutic administration of rIL-18 also resulted in decreased outgrowth of C. albicans in the kidneys and increased levels of interferon- gamma, both in the circulation and after in vitro stimulation of splenocytes with C. albicans. Histopathologic analysis of the kidneys showed increased inflammation and decreased growth of C. albicans in rIL-18-treated mice. In conclusion, rIL-18 improves outcome of disseminated candidiasis in mice and may prove useful as adjuvant immunotherapy of fungal infections.

MeSH terms

  • Animals
  • Candida albicans / growth & development*
  • Candidiasis / drug therapy*
  • Candidiasis / immunology
  • Candidiasis / pathology
  • Candidiasis / prevention & control
  • Female
  • Histocytochemistry
  • Immunotherapy / methods
  • Interferon-gamma / blood
  • Interferon-gamma / immunology
  • Interleukin-18 / pharmacology*
  • Kidney / microbiology
  • Kidney / pathology
  • Mice
  • Mice, Inbred CBA
  • Recombinant Proteins / pharmacology

Substances

  • Interleukin-18
  • Recombinant Proteins
  • Interferon-gamma